IL17A and psoriatic arthritis: Among those, 14,390 received an IL-17 blocker [SEC 7,264 (psoriasis 3,703, psoriatic arthritis 1,672, ankylosing spondylitis 801, rheumatoid arthritis 1,088), IXE 3,605 (psoriasis 2,745, psoriatic arthritis 455, rheumatoid arthritis 405), BRO 3,521 (psoriasis 3,189, psoriatic arthritis 113, rheumatoid arthritis 219) (Tables 1 and 2)].